Emtricitabine/tenofovir disoproxil fumarate

Drug Profile

Emtricitabine/tenofovir disoproxil fumarate

Alternative Names: Emtriva®/Viread®; F/TDF; FTC/TDF; TDF/FTC; Tenofovir disoproxil fumarate/emtricitabine; Truvada; TVD; Viread®/Emtriva®

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Developer Gador; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; Stendhal Mexico; University of Alberta; University of Washington
  • Class Antiretrovirals; Deoxyribonucleosides; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase III Hepatitis B
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 25 Oct 2017 Chemical structure information added
  • 21 Sep 2017 International Partnership for Microbicides and Gilead Sciences withdraws the phase II REACH study for HIV-1 infection (Prevention, In volunteers, In adolescent, In adult) in South Africa prior to enrolment, as it was transferred to partner who will conduct under its own IND (NCT03074786)
  • 14 Mar 2017 International Partnership for Microbicides and Gilead Sciences plan the REACH phase II trial for HIV infection (Prevention, In volunteers, Combination therapy) in South Africa (NCT03074786)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top